Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Chief Commercial

The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $2,612,718 for Chief Commercial in fiscal 2022, including a base salary of $457,333. Disclosed compensation is on record for 4 fiscal years.

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Arcutis Biotherapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Leadership on record at Karyopharm Therapeutics Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Karyopharm Therapeutics Inc. (KPTI) $457,333 $2,612,718
2021 Arcutis Biotherapeutics, Inc. (ARQT) $373,333 $1,564,381
2020 Arcutis Biotherapeutics, Inc. (ARQT) $335,000 $1,267,692
2019 Arcutis Biotherapeutics, Inc. (ARQT) $66,932 $766,075

Recent activity

No call appearances or filed executive changes recorded yet.